Menu
Back to Journals » Clinical Ophthalmology » Volume 6
Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
Authors Ermis SS
Received 15 March 2012
Accepted for publication 3 April 2012
Published 7 May 2012 Volume 2012:6 Pages 673—678
DOI https://doi.org/10.2147/OPTH.S24248
Review by Single anonymous peer review
Peer reviewer comments 2
Sitki Samet Ermiş
Faculty of Medicine, Balikesir University, Tip Fakültesi, Çagis Kampüsü, Balikesir, Turkey
Abstract: Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients' quality of life and may cause poor compliance, which leads to poor intraocular pressure control. To minimize the side effects of long-term treatment, preparations with lower benzalkonium chloride concentrations, preservative-free preparations and alternative preservatives have been developed and reported to have a lower rate of side effects. Tafluprost, launched on the ophthalmic market in 2008, is a new 16-phenoxy analogue of prostaglandin F2α, clinically used as an ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. The safety and intraocular pressure-lowering efficacy of tafluprost has been demonstrated in various preclinical and clinical studies.
Keywords: tafluprost, AFP 168, glaucoma, intraocular pressure, preservative
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.